ALLO vs CTAS · rev $22.0K vs P/E 51, rev $10.34B
Allogene Therapeutics Inc (ALLO) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
ALLO currently screens at market cap $258.1M. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the ALLO and CTAS stock pages for the full models.
Not investment advice.